Independent minds. Global perspective. A publication for the builders
Biotechnology / San Francisco

Nizar Batada.

Founder
Eugit Therapeutics

Nizar Batada co-founded Eugit Therapeutics with George Church after research at 23andMe and the University of Edinburgh. He earned a biophysics doctorate at Stanford and has experience in genomics and cancer research. Eugit develops targeted therapeutic approaches using immune-system biology.

Public-source researchLast checked 1 source ↘
THE STORY, IN CONTEXT

Nizar Batada and the story of Eugit Therapeutics.

Eugit's earlier launch described immune-cell research for several cancers and connected that work to Batada's prior discoveries. The current company description instead emphasizes targeted delivery for tissue-specific inflammatory disease, with an initial bowel-disease focus. Those are different development contexts, and the source does not explain the complete transition. It supports Batada's scientific background, but does not establish clinical efficacy, safety, trial timing or a treatment recommendation.

FROM THE PUBLIC RECORD

Public advice & further reading.

No personal advice is attributed in this profile: a verifiable public advice source has not yet been established. The company and activity facts above remain separately sourced.

Suggest a first-person interview or essay ↗
EVIDENCE IN PLAIN SIGHT

Sources & attribution.

  1. 01
    Eugit Therapeutics — Y Combinator company and active founder profile

    Public active-founder biography, current company status and description, and founding-team launch accounts. Company or team statements are attributed accounts, not independently audited performance results.

    www.ycombinator.com
About this profile

Independently researched from the public sources above. Featured people and companies are not affiliated with BusinessBlogz. Source dates and attribution provide context for the information shown; business claims remain attributed to their original source. Role and company details can change after review. The initials graphic is editorial artwork, not a photograph.

Request a correction or update ↗
KEEP EXPLORING

More builders in Biotechnology.

Explore the sector ↗